Mycophenolate for the treatment of autoimmune hepatitis: Prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients

Journal of Hepatology

Volumn 55, Issue 3, 2011, Pages 636-646

  Zachou, Kalliopi ^a,b   Gatselis, Nikolaos ^a   Papadamou, Georgia ^a   Rigopoulou, Eirini I ^a   Dalekos, George N ^a,b  

^a UNIVERSITY OF THESSALY   (Greece)

^b INSTITUTE OF HUMAN PERFORMANCE AND REHABILITATION   (Greece)

Author keywords

Autoimmune hepatitis; Cirrhosis; Liver autoimmunity; Mycophenolate mofetil

Indexed keywords

AMINOTRANSFERASE; CORTICOSTEROID; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; PREDNISOLONE; STEROID;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BIOCHEMISTRY; COHORT ANALYSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; SEPTICEMIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860389502     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.12.032     Document Type: Article

References (49)

1. D.P. Bogdanos, and G.N. Dalekos Enzymes as target antigens of liver specific autoimmunity: the case of cytochromes P450s Curr Med Chem 15 2008 2285 2292
2. E.L. Krawitt Autoimmune hepatitis N Engl J Med 354 2006 54 66 (Pubitemid 43048951)
3. K. Zachou, E. Rigopoulou, and G.N. Dalekos Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease J Autoimm Dis 1 2004 2
4. R.D. Soloway, W.H. Summerskill, and A.H. Baggenstoss Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis Gastroenterology 63 1972 820 833
5. A.P. Kirk, S. Jain, and S. Pocock Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis Gut 21 1980 78 83 (Pubitemid 10157086)
6. G.C. Cook, R. Mulligan, and S. Sherlock Controlled prospective trial of corticosteroid therapy in active chronic hepatitis Q J Med 158 1971 159 185
7. I.M. Murray-Lyon, R.B. Stern, and R. Williams Controlled trial of prednisone and azathioprine in active chronic hepatitis Lancet 1 1973 735 737
8. W.H.J. Summerskill, M.G. Korman, H.V. Ammon, and A.H. Baggenstoss Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared Gut 16 1975 876 883
9. A.J. Czaja Current and future treatments of autoimmune hepatitis Expert Rev Gastroenterol Hepatol 3 2009 269 291
10. S. Seela, H. Sheela, and J.L. Boyer Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy Liver Int 25 2005 734 739 (Pubitemid 41038654)
11. A.J. Czaja, S.J. Beaver, and M.T. Shiels Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis Gastroenterology 92 1987 215 219 (Pubitemid 17207684)
12. A.J. Montano-Loza, H.A. Carpenter, and A.J. Czaja Consequences of treatment withdrawal in type 1 autoimmune hepatitis Liver Int 27 2007 507 515 (Pubitemid 46534573)
13. P.J. Johnson, I.G. McJFarlane, and R. Williams Azathioprine for long-term maintenance of remission in autoimmune hepatitis N Engl J Med 333 1995 958 963
14. A.J. Czaja Safety issues in the management of autoimmune hepatitis Expert Opin Drug Saf 7 2008 319 333 (Pubitemid 351802831)
15. S. Sahasranaman, D. Howard, and S. Roy Clinical pharmacology and pharmacogenetics of thiopurines Eur J Clin Pharmacol 64 2008 753 767
16. A. Tamori, M. Shinzaki, and S. Kosaka Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases Liver Int 27 2007 95 100 (Pubitemid 46139433)
17. D. Vergani, M.S. Longi, D.P. Bogdanos, Y. Ma, and G.M. Vergani Autoimmune hepatitis Semin Immunopathol 31 2009 421 435
18. Y.H. Oo, and J. Neuberger Use of mycophanolate in the treatment of autoimmune hepatitis Liver Int 25 2005 687 691 (Pubitemid 41038648)
19. K.E. Sherman, M. Narkewicz, and C.P. Pinto Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis J Ηepatol 21 1994 1040 1047
20. D.H. Van Thiel, H. Wright, and P. Carrol Tacrolimus: a potential new treatment for autoimmune chronic hepatitis: results of an open-label preliminary trial Am J Gastroenterol 90 1995 771 777
21. F. Alvarez, M. Ciocca, and C. Canero-Velasco Short-term cyclosporine induces a remission of autoimmune hepatitis in children J Hepatol 30 1999 222 227 (Pubitemid 29071183)
22. A.C. Allison Mechanisms of action of mycophenolate mofetil Lupus 14 2005 s2 s8 (Pubitemid 40460509)
23. L. Iaccarino, M. Rampudda, M. Canova, S. Della Libera, P. Sarzi-Puttinic, and A. Doria Mycophenolate mofetil: what is its place in the treatment of autoimmune rheumatic diseases? Autoimmunity Rev 6 2007 190 195 (Pubitemid 46187338)
24. P.D. Richardson, P.D. James, and S.D. Ryder Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine J Hepatol 33 2000 371 375 (Pubitemid 30663373)
25. S.M. Devlin, M.G. Swain, S.J. Urbanski, and K.W. Burak Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy Can J Gastroenterol 18 2004 321 326 (Pubitemid 38801788)
26. N. Chatur, A. Ramji, and V.G. Bain Transplant immunosupressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus Liver Int 25 2005 723 727 (Pubitemid 41038652)
27. A.J. Czaja, and H.A. Carpenter Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease J Clin Gastroenterol 39 2005 819 825 (Pubitemid 41361901)
28. I. Inductivo-Yu, A. Adams, and R.G. Gish Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy Clin Gastroenterol Hepatol 5 2007 799 802 (Pubitemid 47031057)
29. E.M. Hennes, Y.H. Oo, and C. Schramm Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 103 2008 3063 3070
30. M.M. Aw, A. Dhawan, M. Samyn, A. Bargiota, and G. Mieli-Vergani Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up J Hepatol 51 2009 156 160
31. D.C. Wolf, L. Bojito, M. Facciuto, and E. Lebovics Mycophenolate Mofetil for autoimmune hepatitis: a single practice experience Dig Dis Sci 54 2009 2519 2522
32. J.T. Hlivko, M.L. Shiffman, and R.T. Stravitz A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis Clin Gastroenterol Hepatol 6 2008 1036 1040
33. F. Alvarez, P.A. Berg, and F.B. Bianchi International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis J Hepatol 31 1999 929 938 (Pubitemid 29514229)
34. E.M. Hennes, M. Zeniya, and A.J. Czaja Simplified criteria for the diagnosis of autoimmune hepatitis Hepatology 48 2008 169 176 (Pubitemid 351975541)
35. S. Kanzler, G. Gerken, and H. Lohr Duration of immunosuppressive therapy in autoimmune hepatitis J Hepatol 34 2001 354 355
36. R.G. Knodell, K.G. Ishak, and W.C. Black Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1 1981 431 435 (Pubitemid 12218164)
37. S.P. Georgiadou, K. Zachou, C. Liaskos, S. Gabeta, E.I. Rigopoulou, and G.N. Dalekos Occult hepatitis B virus infection in patients with autoimmune liver diseases Liver Int 29 2009 434 442
38. A.E. Germenis, E.E. Yiannaki, and K. Zachou Prevalence and clinical significance of immunoglobulin A antibodies against tissue transglutaminase in patients with diverse chronic liver diseases Clin Diagn Lab Immunol 12 2005 941 948
39. T.A. Zografos, E.I. Rigopoulou, and C. Liaskos Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis J Hepatol 44 2006 848 855
40. P. Muratori, A. Granito, and C. Quarneti Autoimmune hepatitis in Italy: the Bologna experience J Hepatol 50 2009 1210 1218
41. M.H.M. Lamers, M.G.H. van Oijen, and M. Pronk Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials J Hepatol 53 2010 191 198
42. A.J. Czaja Rapidity of treatment response and outcome in type 1 autoimmune hepatitis J Hepatol 51 2009 161 167
43. Y. Miyake, Y. Iwasaki, and R. Terada Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis J Hepatol 43 2005 951 957 (Pubitemid 41627979)
44. A. Czaja Features and consequences of untreated autoimmune hepatitis Liver Int 29 2009 816 823
45. M.P. Manns, A.J. Czaja, and J.D. Gorham Diagnosis and management of autoimmune hepatitis Hepatology 51 2010 2193 2213
46. R.H. Wiesner, J.S. Shorr, B.J. Steffen, A.H. Chu, R.D. Gordon, and J.R. Lake Mycophenolate mofetil combination therapy improves longterm outcomes after liver transplantation in patients with and without hepatitis C Liver Transpl 11 2005 750 759 (Pubitemid 40975576)
47. European Mycophenolate Mofetil Cooperative Study Group Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection Lancet 345 1995 1321 1325
48. J.J. Feld, H. Dinh, T. Arenovich, V.A. Marcus, I.R. Wanless, and E.J. Heathcote Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome Hepatology 42 2005 53 62 (Pubitemid 40911311)
49. M.A. Heneghan, T. Al-Chalabi, and I.G. McFarlane Cost-effectiveness of pharmacotherapy for autoimmune hepatitis Expert Opin Pharmacother 7 2006 145 156